OVERVIEW

Patient Point of View: PDE4 Inhibitors for the Treatment of Adult Plaque Psoriasis is organized by i3 Health.

Dates Available:
September 25, 2024 - September 24, 2025

Statement of Need:
Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly impacts affected individuals’ quality of life. The most common subtype is plaque psoriasis, characterized by erythematous to violaceous plaques covered with scales. Due to the substantial symptom burden of plaque psoriasis and challenges surrounding medication tolerability and adherence, innovative treatment options are needed. Phosphodiesterase-4 (PDE4) inhibitors, which play a key role in the inflammatory cascade by degrading cAMP and contributing to pro-inflammatory mediator production, are emerging as a promising drug class for plaque psoriasis. As PDE4 inhibitors demonstrate efficacy in clinical trials and receive approval, it is crucial that members of the interdisciplinary care team develop patient education strategies that address safety concerns, foster communication, and promote adherence to therapy (Crowley & Gooderham, 2024). In this activity, Steven R. Feldman, MD, PhD, Professor of Dermatology, Pathology, and Social Sciences & Health Policy at Wake Forest University School of Medicine, and Sara Richardson, plaque psoriasis patient, provide insights into the patient point of view on PDE4 inhibitors for the treatment of adult plaque psoriasis.

Learning Objectives:
Upon completion of this activity, participants should be able to

Discuss the scientific rationale behind targeting PDE4 in the treatment of plaque psoriasis
Evaluate the latest clinical evidence on the efficacy and safety of PDE4 inhibitors for moderate-to-severe plaque psoriasis
Develop patient education strategies that foster open communication, address safety concerns, and promote adherence to plaque psoriasis therapy

In this activity, Steven R. Feldman, MD, PhD, Professor of Dermatology, Pathology, and Social Sciences & Health Policy at Wake Forest University School of Medicine, and Sara Richardson, plaque psoriasis patient, provide insights into the patient point of view on PDE4 inhibitors for the treatment of adult plaque psoriasis.

ACCREDITATION & CREDITS

Jointly Accredited Provider
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 9/24/2025. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development
A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.0 ANCC contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, for 1.0 ANCC contact hour.

Continuing Pharmacy Education
i3 Health has approved this knowledge-based activity for 1.0 ACPE CE hour. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.

1 AMA PRA Category 1 Credit™

1 MOC

1 Contact Hour

1 CE Hours

FACULTY

Steven Feldman

MD, PhDDermatology, Dermatopathology

TARGET AUDIENCE

PhysicianNursingPharmacistPhysician AssistantDermatologistsHealthcare ProfessionalsNursesPrimary Care PhysiciansNurse PractitionersDermatology ResidentsMedical Oncologists